{"id":910095,"date":"2025-11-14T07:28:49","date_gmt":"2025-11-14T12:28:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-updates\/"},"modified":"2025-11-14T07:28:49","modified_gmt":"2025-11-14T12:28:49","slug":"marker-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/marker-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-updates\/","title":{"rendered":"Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates"},"content":{"rendered":"
\n

\n APOLLO study showed encouraging overall responses and favorable safety profile in relapsed\/refractory B-cell lymphoma\u00a0<\/em>\n <\/p>\n

\n MT-601 demonstrated 66% objective response rate with 50% complete response in relapsed Non-Hodgkin lymphoma (NHL) patients in the ongoing APOLLO study<\/em>\n <\/p>\n

\n First patient treated in Off-the-Shelf program (RAPID study) investigating MAR-T cells in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) <\/em>\n <\/p>\n

\n cGMP manufacturing collaboration established with Cellipont Bioservices<\/em>\n <\/p>\n

HOUSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing next-generation T cell-based therapies, today reported corporate updates and financial results for the third quarter ended September 30, 2025.<\/p>\n

\u201cMarker entered the second half of 2025 with strong clinical momentum as we continue to advance our lead program, MT-601, in patients with relapsed or refractory B-cell lymphoma,\u201d said Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics.<\/strong> \u201cThe most recent update from our Phase 1 APOLLO study showed a 66% objective response rate including 50% complete responses, in heavily pre-treated NHL patients. These data, together with a favorable safety profile, reinforce the potential of MT-601 to meet the critical needs of patients who have exhausted multiple lines of therapy, including CAR-T cell therapies and bispecific antibodies. We\u2019re encouraged by the durability of responses and plan to share an additional update in the first half of 2026.\u201d<\/p>\n

Dr. Vera continued, \u201cWe also achieved a number of key milestones in this quarter, including treating the first patient in our Off-the-Shelf (OTS) program and entering a strategic manufacturing collaboration with Cellipont to scale up production of MT-601. In parallel, we have strengthened our balance sheet by raising approximately $10 million through our ATM facility, extending our cash runway well into 2026. Looking ahead, we are focused on enrolling patients in the MT-601 dose expansion cohort to build on our promising observations from our APOLLO study. Having executed on the priorities we set at the beginning of the year we are entering the final stretch of 2025 with strong operational footing and a clear clinical focus.\u201d<\/p>\n

\n PROGRAM UPDATES & OPERATIONAL HIGHLIGHTS<\/strong>\n <\/p>\n

\n MT-601 (Lymphoma)<\/strong>\n <\/p>\n